Bristol-Myers Squibb paid $150 million to settle SEC channel-stuffing and reserve charges
Bristol-Myers Squibb Company · Pharmaceuticals
The case in brief
Visible before detection
Checks that could have surfaced it, on hindsight
Operating-metric verification
Wholesaler inventory and end-user demand data would show sales running ahead of consumption.
Can mislead when: Contract staff do not appear in EPFO. Vahan access needs licensed APIs. Some businesses have no physical trace.
Third-party confirmation
Confirmation from the two largest wholesalers would show stock held and any return rights.
Can mislead when: Counterparties can collude or ignore requests. A non-response is logged as a gap, never as a pass.
Books edit log
Reserve release entries would be visible in the accounting log.
Can mislead when: Logs can be disabled at database level (auditors qualified this in year one) or tampered with on export. Kubr needs the company to cooperate.
Where Kubr services would have helped
Financial diligence
Offered in India- C10 Wholesaler inventory and end-user demand data would show sales running ahead of consumption.
- C12 Reserve release entries would be visible in the accounting log.
Valuation context
Offered in India- Peer multiples and the exit-multiple bridge would have shown how much of the story relied on valuation holding.
Model check
Offered in India- C10 Wholesaler inventory and end-user demand data would show sales running ahead of consumption.
Portfolio monitor
Offered in India- C10 Wholesaler inventory and end-user demand data would show sales running ahead of consumption.
Mapped from the checks each service runs. A hindsight reading of public records, not a promise that the failure would have been found.
Same pattern
A summary of public documents. It reports what the sources say. It is not Kubr's finding and not a statement of guilt.